LIMITED SLOTS AVAILABLE!

PDO Screen

Patient-derived colorectal cancer organoid screening platform

Test your compound efficacy directly on patient avatars to uncover the therapeutic potential of your agent early in the drug development pipeline.

Screen features:

ATP-based cell-viability assay with IC₅₀ readouts
3D assay format with 96/384-well plate format
Test up to 10 compounds in triplicates
A preset panel of CRC organoid models capturing key cancer drivers
Matched tumor-normal organoid pairs available to uncover off-tumor toxicities